Kanorskiĭ S G
Kardiologiia. 2015;55(2):96-101.
Of 10,261 patients with type 2 diabetes who survived to the end of a randomized ADVANCE trial 83% were included in the ADVANCE-ON project for observation for 6 years. The difference in the level of blood pressure which had been achieved during 4.5 years of within trial treatment with fixed perindopril/indapamide combination quickly vanished but significant decrease of total and cardiovascular mortality in the group of patients treated with this combination for 4.5 years was sustained during 6 years of post-trial follow-up. The results can be related to gradually weakening protective effect of perindopril/indapamide combination on cardiovascular system, and are indicative of the expedience of long-term use of this antihypertensive therapy for maximal lowering of mortality of patients with diabetes.
在一项随机对照的ADVANCE试验中，10261例2型糖尿病患者存活至试验结束，其中83%被纳入ADVANCE-ON项目进行为期6年的观察。在试验期间使用固定剂量培哚普利/吲达帕胺联合治疗4.5年时所达到的血压水平差异迅速消失，但在试验后6年的随访中，接受该联合治疗4.5年的患者组的总死亡率和心血管死亡率仍显著降低。这些结果可能与培哚普利/吲达帕胺联合治疗对心血管系统的保护作用逐渐减弱有关，表明长期使用这种抗高血压疗法对于最大程度降低糖尿病患者的死亡率是适宜的。
